首页> 美国卫生研究院文献>Iranian Journal of Pharmaceutical Research : IJPR >Novel Colchicine Analogues Target Mitochondrial PT Pores Using Free Tubulins and Induce ROS-Mediated Apoptosis in Cancerous Lymphocytes
【2h】

Novel Colchicine Analogues Target Mitochondrial PT Pores Using Free Tubulins and Induce ROS-Mediated Apoptosis in Cancerous Lymphocytes

机译:新型秋水仙碱类似物使用游离微管蛋白靶向线粒体PT毛孔并诱导ROS介导癌细胞中的凋亡。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

B-acute lymphoblastic leukemia (B-ALL) is the frequent pediatric malignity. Chemotherapy is the most practical approaches to deal with such malignancies. Microtubule-targeted agents are one of the most strategic drugs which formerly used in chemotherapy. Although colchicine-binding anti-tubulin agents exhibited promising effects in clinical trials, their exact mechanism of action is not fully understood. In this study, the effects of two newly synthesized of colchicine derivatives were investigated on cell viability of cancerous and normal lymphocytes. The viability test was carried out by MTT assay. Apoptosis vs. necrosis was measured by double staining with annexin V/PI, and caspase-3 as the ultimate mediator of apoptotic measured through the colorimetric assay. Parameters of mitochondrial damage (ROS formation, MMP (Mitochondrial Membrane Potential) decline, mitochondrial swelling, and cytochrome c release following treatment by colchicine derivatives. By focusing on mitochondrial parameters, we showed that following treatment by two newly synthesized colchicine derivatives, apoptosis is triggered in cancerous B-lymphocytes. We demonstrated these compounds could activate apoptosis in cancerous lymphocytes by augmentation of reactive oxygen species (ROS), a decline in mitochondrial membrane potential (MMP), mitochondrial swelling, release of cytochrome c, and also caspase-3 activation. Considering the obtained evidence, these inhibitors could be the new therapeutic strategies in ALL treatment.
机译:B急性淋巴细胞白血病(B-ALL)是儿童恶性肿瘤的常见病。化学疗法是治疗此类恶性肿瘤的最实用方法。以微管为靶标的药物是以前用于化学疗法的最具战略意义的药物之一。尽管秋水仙碱结合的抗微管蛋白药物在临床试验中显示出令人鼓舞的效果,但其确切的作用机理尚未完全了解。在这项研究中,研究了两种新合成的秋水仙碱衍生物对癌细胞和正常淋巴细胞的细胞活力的影响。通过MTT测定法进行生存力测试。通过膜联蛋白V / PI的双重染色,通过比色法测量凋亡和坏死的凋亡,并通过caspase-3作为凋亡的终极介质进行两次染色。秋水仙碱衍生物处理后的线粒体损伤参数(ROS形成,MMP(线粒体膜电位)下降,线粒体肿胀和细胞色素c释放。通过关注线粒体参数,我们发现在用两种新合成的秋水仙碱衍生物处理后,触发了凋亡我们证明了这些化合物可以通过增加活性氧(ROS),降低线粒体膜电位(MMP),线粒体肿胀,释放细胞色素c以及激活caspase-3激活来激活癌细胞的凋亡考虑到获得的证据,这些抑制剂可能是ALL治疗中的新治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号